INO · Inovio Pharmaceuticals, Inc. · Executive Compensation
$0.93
+0.04 (+4.34%)
At close · Oct 28
View the 10-K filed Mar 12, 2026
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Customer concentration
— key customers 100% of revenue
Key customers — 100% of revenue (the years ended December 31, 2025 and 2024)
“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
Market Cap
$92.02M
Shares
103.40M
Volume · Oct 28
4.57M
Avg daily vol (3M)
4.53M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jacqueline E. Shea | President and Chief Executive Officer | $1,587,155 |
| Jacqueline Shea | President and Chief Executive Officer | $1,587,155 |
| Michael Sumner | M.D. Chief Medical Officer and Head of Development | $910,636 |
| Peter D. Kies | Chief Financial Officer | $833,684 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jacqueline E. Shea | President and Chief Executive Officer | $2,050,669 |
| Jacqueline Shea | President and Chief Executive Officer | $2,050,669 |
| Michael Sumner | M.D. Chief Medical Officer | $1,037,406 |
| Peter D. Kies | Chief Financial Officer | $940,072 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jacqueline Shea | President and Chief Executive Officer | $2,438,908 |
| Jacqueline E. Shea | President and Chief Executive Officer | $2,438,908 |
| Peter D. Kies | Chief Financial Officer | $1,161,040 |
| Laurent M. Humeau | Ph.D. Chief Scientific Officer | $1,144,927 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | Former President and Chief Executive Officer | $10,472,297 |
| Jacqueline E. Shea | President and Chief Executive Officer | $3,519,118 |
| Jacqueline Shea | President and Chief Executive Officer | $3,519,118 |
| Peter D. Kies | Chief Financial Officer | $1,618,468 |
| Laurent M. Humeau | Ph.D. Chief Scientific Officer | $1,570,461 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | Former President and Chief Executive Officer | $6,223,600 |
| Jacqueline Shea | President and Chief Executive Officer | $2,310,157 |
| Jacqueline E. Shea | President and Chief Executive Officer | $2,310,157 |
| Peter D. Kies | Chief Financial Officer | $2,297,817 |
| Laurent M. Humeau | Chief Scientific Officer | $2,283,569 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | President and Chief Executive Officer | $4,707,676 |
| Peter D. Kies | Chief Financial Officer | $2,153,905 |
| Laurent M. Humeau | Chief Scientific Officer | $2,137,365 |
| Jacqueline E. Shea | Chief Operating Officer | $2,137,311 |
| Jacqueline Shea | Chief Operating Officer | $2,137,311 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | President and Chief Executive Officer | $2,588,534 |
| Mark L. Bagarazzi | Former Chief Medical Officer | $2,324,930 |
| Jacqueline E. Shea | Chief Operating Officer | $1,157,034 |
| Jacqueline Shea | Chief Operating Officer | $1,157,034 |
| Peter D. Kies | Chief Financial Officer | $1,142,936 |
| Laurent M. Humeau | Chief Scientific Officer | $972,531 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | President and Chief Executive Officer | $3,081,043 |
| Mark L. Bagarazzi | Former Chief Medical Officer | $1,345,888 |
| Peter D. Kies | Chief Financial Officer | $1,331,612 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | President, Chief Executive Officer and Director | $4,389,268 |
| Peter D. Kies | Chief Financial Officer | $1,447,387 |
| Mark L. Bagarazzi | Former Chief Medical Officer | $1,444,719 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lota S. Zoth | director | Appointed | 2023-05-18 |
| Wendy L. Yarno | director | Appointed | 2023-05-18 |
| David B. Weiner, Ph.D. | director | Appointed | 2023-05-18 |
| Jay P. Shepard | director | Appointed | 2023-05-18 |
| Ann C. Miller, M.D. | director | Appointed | 2023-05-18 |
| Jacqueline E. Shea, Ph.D. | director | Appointed | 2023-05-18 |
| Roger D. Dansey, M.D. | director | Appointed | 2023-05-18 |
| Simon X. Benito | director | Appointed | 2023-05-18 |
Leadership
- Jacqueline E. Shea CEO, COO, Board Member
- Jacqueline Shea CEO, COO, Board Member
- Simon X. Benito Chairman, Board Member
- Peter D. Kies CFO
- Ann C. Miller, M.D. Board Member
- David B. Weiner, Ph.D. Board Member
- Jacqueline E. Shea, Ph.D. Board Member
- Jay Shepard Board Member
- Roger D. Dansey, M.D. Board Member
- Roger Dansey Board Member
Key facts
CIK
1055726
CUSIP
45773H409
13F (30d)
22 filings
22 filers
Visit website
Investor relations